Overview

Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma

Status:
RECRUITING
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Evaluation of the efficacy and safety of Xidabenzamide combined with AK112 for advanced bone and soft tissue sarcoma of second-line and above.
Phase:
PHASE2
Details
Lead Sponsor:
Shanxi Province Cancer Hospital
Treatments:
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide